Trends in Spending and Claims for P2Y12 Inhibitors by Medicare and Medicaid From 2015 to 2020

被引：1
|
作者：
Essa, Mohammed [2 ]
Ross, Joseph S. S. [3 ,4 ,5 ]
Dhruva, Sanket S. S. [6 ]
Desai, Nihar R. R. [7 ]
Yeh, Robert W. W. [8 ]
Faridi, Kamil F. F. [1 ,7 ]
机构：
[1] Yale Sch Med, Dept Med, Sect Cardiovasc Med, Courier 333 Cedar St,Off 310 Dana, New Haven, CT 06520 USA
[2] Catholic Med Ctr, New England Heart & Vasc Inst, Manchester, NH USA
[3] Yale New Haven Hlth Syst, Ctr Outcomes Res & Evaluat, New Haven, CT USA
[4] Yale Sch Med, Dept Med, Sect Gen Internal Med, New Haven, CT 06520 USA
[5] Yale Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT USA
[6] Univ Calif San Francisco, Sch Med, Dept Med, Sect Cardiol, San Francisco, CA USA
[7] Yale New Haven Hlth Syst, Ctr Outcomes Res & Evaluat, Yale Sch Med, Sect Cardiovasc Med,Dept Med, New Haven, CT USA
[8] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA USA
来源：
JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2023年 / 12卷 / 08期
关键词：
clopidogrel; medication costs; prasugrel; ticagrelor;
D O I：
10.1161/JAHA.122.028869
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Republished Education in Heart: New P2Y12 inhibitors
    Storey, Robert F.
    POSTGRADUATE MEDICAL JOURNAL, 2012, 88 (1035) : 49 - 54
  • [22] P2Y12 Inhibitors in Cardiovascular Disease: Focus on Prasugrel
    Scott, Day Marice
    Norwood, Rhonda M.
    Parra, David
    ANNALS OF PHARMACOTHERAPY, 2009, 43 (01) : 64 - 76
  • [23] P2Y12 inhibitors: do they increase cancer risk?
    Fierro, Joseph J.
    Cave, Brandon
    Khouzam, Rami N.
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (17)
  • [24] Trends for and Clinical Factors Associated with Choice of Oral P2Y12 Inhibitors for Patients on Chronic Dialysis
    Jain, Nishank
    Hunt, Suzanne L.
    Cui, Huizhong
    Phadnis, Milind A.
    Mahnken, Jonathan D.
    Shireman, Theresa I.
    Dai, Junqiang
    Mehta, Jawahar L.
    Rasu, Rafia S.
    CARDIOVASCULAR DRUGS AND THERAPY, 2019, 33 (05) : 511 - 521
  • [25] Trends for and Clinical Factors Associated with Choice of Oral P2Y12 Inhibitors for Patients on Chronic Dialysis
    Nishank Jain
    Suzanne L. Hunt
    Huizhong Cui
    Milind A. Phadnis
    Jonathan D. Mahnken
    Theresa I. Shireman
    Junqiang Dai
    Jawahar L. Mehta
    Rafia S. Rasu
    Cardiovascular Drugs and Therapy, 2019, 33 : 511 - 521
  • [26] Potent P2Y12 inhibitors in elderly population, insigth from praise registry
    Elia, Edoardo
    D'Ascenzo, Fabrizio
    Breviario, Susanna
    Bruno, Francesco
    Marengo, Giorgio
    De Filippo, Ovidio
    Conrotto, Federico
    De Ferrari, Gaetano Maria
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (0G)
  • [27] Potent P2Y12 inhibitors in elderly population, insigth from praise registry
    Elia, Edoardo
    D'Ascenzo, Fabrizio
    Breviario, Susanna
    Bruno, Francesco
    Marengo, Giorgio
    De Filippo, Ovidio
    Conrotto, Federico
    De Ferrari, Gaetano Maria
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (SUPPL G)
  • [28] Challenge in Predicting Persistence to P2Y12 Inhibitors: A Perspective From the ARTEMIS Trial
    Rymer, Jennifer A.
    Wegermann, Zachary K.
    Kaltenbach, Lisa A.
    Webb, Laura E.
    Peterson, Eric D.
    Wang, Tracy Y.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2023, 12 (12):
  • [29] Antiplatelet Therapy n ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors
    Ristorto, Jessica
    Messas, Nathan
    Marchandot, Benjamin
    Kibler, Marion
    Hess, Sebastien
    Meyer, Nicolas
    Schaeffer, Michael
    Tuzin, Nicolas
    Ohlmann, Patrick
    Jesel, Laurence
    Morel, Olivier
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2018, 25 (08) : 674 - 689
  • [30] Response Variability to P2Y12 Receptor Inhibitors Expectations and Reality
    Siller-Matula, Jolanta M.
    Trenk, Dietmar
    Schroer, Karsten
    Gawaz, Meinrad
    Kristensen, Steen D.
    Storey, Robert F.
    Huber, Kurt
    JACC-CARDIOVASCULAR INTERVENTIONS, 2013, 6 (11) : 1111 - 1128
12345